A healthcare worker holds a blood sample during a Covid-19 vaccine clinical trial at the American Research Center in Hollywood, Florida, on Wednesday, September 9, 2020.
Eva Marie Uzcategui | Bloomberg | beautiful images
US pharmaceutical giant Pfizer and German biotech company BioNTech say their coronavirus vaccine is 90% more effective in preventing Covid-19 for those who have no evidence of infection. before that, according to data released Monday from their late-stage vaccine trial.
It happened as drug manufacturers and research centers around the world were scrambling to provide a safe and effective vaccine in an effort to end the coronavirus pandemic that took the lives of more than 1. , 25 million people worldwide.
Scientists are expecting a coronavirus vaccine to be at least 75% effective, while White House corona virus advisor Dr. Anthony Fauci previously said that a vaccine was effective. 50% or 60% fruit will be accepted.
Albert Bourla, President and CEO of Pfizer, hailed the development as “a great day for science and humanity.”
The results were based on the first interim efficacy analysis conducted by the independent and external Data Monitoring Committee from the third phase clinical study. An independent team of experts oversees US clinical trials to ensure the safety of participants.
Analysis and evaluation of 94 Covid-19 infections were confirmed among 43,538 study participants. Pfizer and BioNTech reported a split case between vaccinated people and those given a placebo showed a vaccine efficacy rate of over 90% after seven days after the second dose.
Meaning that protection from Covid-19 is achieved 28 days after the initial vaccination, including a two-dose schedule.
However, the final efficacy percentage for the vaccine is likely to change, as safety and additional data continue to be collected.
“The first set of results from our Phase 3 COVID-19 vaccine trial provides preliminary evidence of the vaccine’s ability to prevent COVID-19,” Pfizer Bourla said in a statement.
“We are reaching this milestone in our vaccine development program at a time when the world needs it most with record-breaking infection rates, hospitals near capacity and economies. Sacrifice is struggling to reopen, “Bourla continued.
“With today’s news, we are taking a more important step in providing people around the world with a much-needed breakthrough to help end this global health crisis. wants to share more efficiency and safety data generated by thousands of participants over the coming weeks. “
About 42% of trial participants were of diverse backgrounds, adding that there have not been any serious safety concerns reported, Pfizer and BioNTech reported.
The companies said they plan to submit an emergency use license soon to the US Food and Drug Administration after they have two-month data, which is currently being tracked for the third week of November. .
Based on current projections, Pfizer and BioNTech are expected to produce up to 50 million doses of vaccine by 2020 and up to 1.3 billion doses by 2021.
The companies said they plan to submit data from the full third phase trial, which starts on July 27, to publish the scientific review.